

## Arş.Gör. CİHAN EROL

### Kişisel Bilgiler

E-posta: cerol@ybu.edu.tr

Web: <https://avesis.aybu.edu.tr/cerol>

### SCI, SSCI ve AHCI İndekslerine Giren Dergilerde Yayınlanan Makaleler

- I. **The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement**  
Bilgin B., ŞENDUR M. A. N. , Yücel Ş., Hizal M., Güner G., Akyürek N., EROL C., AKINCI M. B. , Dede D. Ş. , YALÇIN B., et al.  
Journal of Cancer Research and Clinical Oncology, 2021 (SCI Expanded İndekslerine Giren Dergi)
- II. **The association between antibiotic use and survival in renal cell carcinoma patients treated with immunotherapy: a multi-center study**  
Güven D. C. , Acar R., Yekeduz E., Bilgetekin I., Baytemur N. K. , EROL C., Ceylan F., Sendur M. A. , Demirci U., Urun Y., et al.  
Current Problems in Cancer, 2021 (SCI Expanded İndekslerine Giren Dergi)
- III. **The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study**  
Hizal M., Bilgin B., Paksoy N., Açıköz Ö., Sezer A., Gürbüz M., Ak N., Yücel Ş., Ayhan M., EROL C., et al.  
Journal of Cancer Research and Clinical Oncology, 2021 (SCI Expanded İndekslerine Giren Dergi)

### Diğer Dergilerde Yayınlanan Makaleler

- I. **Trastuzumab ± Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group**  
Gürbüz M., Akkuş E., Sakin A., Urvay S., Demiray A. G. , Şahin S., Şakalar T., EROL C., ŞENDUR M. A. N. , ŞAHİN A. B. , et al.  
Journal of Gastrointestinal Cancer, 2021 (ESCI İndekslerine Giren Dergi)